This article is more than 5 years old. Information may no longer be current.

TCT’s 25th conference promises ‘extraordinary’ content

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The 25th annual Transcatheter Cardiovascular Therapeutics Scientific Symposium is expected to provide the results from much-anticipated research on some of the hottest topics in interventional cardiology. More than 12,000 attendees and 2,000 presentations are expected at the conference, which will be from Oct. 27 to Nov. 1 in San Francisco.

“The content this year is really extraordinary,” Gregg W. Stone, MD, co-director of TCT, said in a conference call with media. “I would say that this is probably the strongest series of late-breaking trials that we’ve received.”

 

Gregg W. Stone

Stone, who is professor of medicine at Columbia University College of Physicians and Surgeons and director of cardiovascular research and education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center, said “there will be no shortage of exciting new data presented,” including from these trials:

• SAFE-PCI for Women, which investigated safety issues for women undergoing PCI, with particular attention paid to transfemoral vs. transradial access. Stone said the findings could be valuable because “we’re always bemoaning the fact that there are not enough women enrolled in interventional cardiology trials.”
• The Extreme Risk arm of the CoreValve trial, which evaluated the performance of the CoreValve percutaneous aortic valve (Medtronic) in patients at extreme risk for surgical aortic valve replacement and is the pivotal trial for the device in the United States.
• EUROMAX, a follow-up to HORIZONS-AMI, in which patients with STEMI were randomly assigned while in an ambulance to treatment with bivalirudin (Angiomax, The Medicines Company) or heparin with or without a glycoprotein IIb/IIIa inhibitor. EUROMAX investigated “many questions that weren’t addressed in HORIZONS-AMI,” Stone said.
• OPTIMIZE, which compared outcomes for dual antiplatelet therapy discontinuation at 3 months vs. 12 months after drug-eluting stent implantation.
• LEVANT 2, which will report 6-month data from the US pivotal trial of a drug-coated balloon (Lutonix, Bard) for use in superficial femoral arteries.
• TRYTON, which is the first US randomized pivotal trial of a dedicated bifurcation stent (Tryton Medical).

Stone said the 25th anniversary edition of TCT will also be notable because it is the first to go paperless. Instead of receiving information on paper, paid attendees will receive a tablet pre-loaded with all the necessary information. In addition, the tablets will enable attendees to offer feedback on presentations in real time, as a digital moderator will lead an electronic discussion during many sessions.

Stay tuned to Cardiology Today and Cardiology Today’s Intervention for news and developments from this year’s TCT meeting. – by Erik Swain